The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...

The five big factors increasing the risk for cognitive decline, dementia or both: diabetes, midlife hypertension or high ...

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug Administration (FDA) has approved three new drugs to treat Alzheimer’s since June 2021 ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

A soon-to-be-published study analyzed more than 6 million patient records to help support a growing link between heart and ...

The money will support the development of Alzheimer's tests specific to tau tangles, the abnormal proteins that form inside ...

Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

Microglia are the brain's resident immune cells. Their job is to patrol the brain's blood vessels looking for invading ...